Top

Published in:

01-07-2015 | Editors' Invited Manuscript

The role of STAT3 in tumor-mediated immune suppression

Authors: Sherise D. Ferguson, Visish M. Srinivasan, Amy B. Heimberger

Published in: Journal of Neuro-Oncology | Issue 3/2015

Abstract

The role of tumor-induced immune modulation in cancer progression is currently a focus of investigation. The signal transducer and activator of transcription 3 (STAT3) is an established molecular hub of immunosuppression, and its signaling pathways are classically overactivated within malignancies. This article will review STAT3 operational mechanisms within the immune system and the tumor microenvironment, with a focus on therapeutic strategies that may impact outcomes for patients with cancer.

Kortylewski M, Yu H (2007) Stat3 as a potential target for cancer immunotherapy. J Immunother 30(2):131–139. doi:10.1097/01.cji.0000211327.76266.65.00002371-200702000-00001 PubMedCrossRef

Kim JE, Patel M, Ruzevick J, Jackson CM, Lim M (2014) STAT3 activation in glioblastoma: biochemical and therapeutic implications. Cancers (Basel) 6(1):376–395. doi:10.3390/cancers6010376 CrossRef

Rebe C, Vegran F, Berger H, Ghiringhelli F (2013) STAT3 activation: a key factor in tumor immunoescape. JAKSTAT 2(1):e23010. doi:10.4161/jkst.23010.2012JAKS0054R PubMedCentralPubMed

Chen F, Xu Y, Luo Y, Zheng D, Song Y, Yu K, Li H, Zhang L, Zhong W, Ji Y (2010) Down-regulation of Stat3 decreases invasion activity and induces apoptosis of human glioma cells. J Mol Neurosci 40(3):353–359. doi:10.1007/s12031-009-9323-3 PubMedCrossRef

Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, Zhang Q, Wu Y, Jiang H, Sun X (2013) STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 25(4):931–938. doi:10.1016/j.cellsig.2013.01.011 PubMedCrossRef

Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–2008PubMedCrossRef

Yu H, Jove R (2004) The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 4(2):97–105PubMedCrossRef

Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ (1998) Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 102(7):1385–1392. doi:10.1172/JCI3785 PubMedCentralPubMedCrossRef

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105–115. doi:10.1016/S1074-7613(00)80011-4

10.

Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111(3):1515–1523. doi:10.1182/blood-2007-04-087734

11.

Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bogler O, Heimberger AB, Rao G (2012) Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14(9):1136–1145. doi:10.1093/neuonc/nos139/nos139 PubMedCentralPubMedCrossRef

12.

Sherry MM, Reeves A, Wu JK, Cochran BH (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27(10):2383–2392. doi:10.1002/stem.185 PubMedCentralPubMedCrossRef

13.

Bandaru A, Devalraju KP, Paidipally P, Dhiman R, Venkatasubramanian S, Barnes PF, Vankayalapati R, Valluri V (2014) Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol 44(7):2013–2024. doi:10.1002/eji.201343680 PubMedCentralPubMedCrossRef

14.

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS (2013) The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3 K inhibition. Clin Cancer Res 19(3):598–609. doi:10.1158/1078-0432.CCR-12-2731 PubMedCrossRef

15.

de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB (2012) Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 3(9):1036–1048

16.

Lin GS, Yang LJ, Wang XF, Chen YP, Tang WL, Chen L, Lin ZX (2014) STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma. Med Oncol 31(4):924. doi:10.1007/s12032-014-0924-5 PubMedCrossRef

17.

Lin GS, Chen YP, Lin ZX, Wang XF, Zheng ZQ, Chen L (2014) STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. Int J Clin Exp Pathol 7(6):3141–3149PubMedCentralPubMed

18.

Tu Y, Zhong Y, Fu J, Cao Y, Fu G, Tian X, Wang B (2011) Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 28(1):15–23. doi:10.1007/s12032-010-9435-1 PubMedCrossRef

19.

Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB (2008) The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228–8235. doi:10.1158/1078-0432.CCR-08-1329 PubMedCentralPubMedCrossRef

20.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, Jove R, Pardoll D, Yu H (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11(12):1314–1321. doi:10.1038/nm1325

21.

Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, Takaki H, Himeno K, Takaesu G, Kobayashi T, Yoshimura A (2006) Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-β1. J Exp Med 203(4):1021–1031PubMedCentralPubMedCrossRef

22.

Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1):41–51. doi:10.1038/nri1995

23.

Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D (2004) Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172(1):464–474PubMedCrossRef

24.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. doi:10.1038/nri2506 PubMedCentralPubMedCrossRef

25.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49–59. doi:10.1007/s00262-008-0523-4 PubMedCentralPubMedCrossRef

26.

Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121(15):2975–2987. doi:10.1182/blood-2012-08-448548 PubMedCentralPubMedCrossRef

27.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI (2007) Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer. Nat Med 13(7):828–835. doi:10.1038/nm1609

28.

Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222:180–191. doi:10.1111/j.1600-065X.2008.00608 PubMedCentralPubMedCrossRef

29.

Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182(9):5693–5701. doi:10.4049/jimmunol.0900092 PubMedCentralPubMedCrossRef

30.

Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172(2):989–999PubMedCrossRef

31.

Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13(6):591–599. doi:10.1093/neuonc/nor042

32.

Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI (2005) Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65(20):9525–9535PubMedCentralPubMedCrossRef

33.

Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42(6):717–727. doi:10.1016/j.ejca.2006.01.003

34.

Yang I, Han SJ, Kaur G, Crane C, Parsa AT (2010) The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 17(1):6–10. doi:10.1016/j.jocn.2009.05.006 PubMedCentralPubMedCrossRef

35.

Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25(3):315–322. doi:10.1007/s10555-006-9001-7 PubMedCrossRef

36.

Lievense LA, Bezemer K, Aerts JG, Hegmans JP (2013) Tumor-associated macrophages in thoracic malignancies. Lung Cancer 80(3):256–262. doi:10.1016/j.lungcan.2013.02.017 PubMedCrossRef

37.

Ding P, Wang W, Wang J, Yang Z, Xue L (2014) Expression of Tumor-Associated Macrophage in Progression of Human Glioma. Cell Biochem Biophys. doi:10.1007/s12013-014-0105-3 PubMedCentral

38.

Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216(1):15–24PubMedCrossRef

39.

Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B (2009) Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 57(13):1458–1467. doi:10.1002/glia.20863 PubMedCrossRef

40.

Fujiwara Y, Komohara Y, Kudo R, Tsurushima K, Ohnishi K, Ikeda T, Takeya M (2011) Oleanolic acid inhibits macrophage differentiation into the M2 phenotype activation of STAT3. Oncol Rep 26(6):1533–1537. doi:10.3892/or.2011.1454 PubMed

41.

Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12(11):1113–1125. doi:10.1093/neuonc/noq082 PubMedCentralPubMedCrossRef

42.

Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25(18):2586–2593PubMedCrossRef

43.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12(18):5423–5434PubMedCrossRef

44.

El Andaloussi A, Lesniak MS (2007) CD4 + CD25 + FoxP3 + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 83(2):145–152PubMedCrossRef

45.

Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN (2008) Incidence and prognostic impact of FoxP3 + regulatory T cells in human gliomas. Clin Cancer Res 14(16):5166–5172. doi:10.1158/1078-0432.CCR-08-0320 PubMedCrossRef

46.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949. doi:10.1038/nm1093 PubMedCrossRef

47.

Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C, Sun Y (2010) Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 136(10):1585–1595. doi:10.1007/s00432-010-0816-9 PubMedCrossRef

48.

Yue Q, Zhang X, Ye HX, Wang Y, Du ZG, Yao Y, Mao Y (2014) The prognostic value of Foxp3 + tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol 116(2):251–259. doi:10.1007/s11060-013-1314-0 PubMedCentralPubMedCrossRef

49.

Doucette TA, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB (2013) Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res 1(2):112–122PubMedCrossRef

50.

Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J (2006) IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108(5):1571–1579. doi:blood-2006-02-004747

51.

Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM (2014) Th17 cells in cancer: the ultimate identity crisis. Front Immunol 5:276. doi:10.3389/fimmu.2014.00276 PubMedCentralPubMedCrossRef

52.

Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM, Kirby MR, Belkaid Y, Schwartzberg PL (2014) Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med 211(3):529–543. doi:10.1084/jem.20131459

53.

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rebe C, Ghiringhelli F (2012) Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36(3):362–373. doi:10.1016/j.immuni.2011.12.019 PubMedCrossRef

54.

Albesiano E, Han JE, Lim M (2010) Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 21(1):17–29. doi:10.1016/j.nec.2009.08.008 PubMedCrossRef

55.

Rolle CE, Sengupta S, Lesniak MS (2012) Mechanisms of immune evasion by gliomas. Adv Exp Med Biol 746:53–76. doi:10.1007/978-1-4614-3146-6_5 PubMedCrossRef

56.

Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180(4):2089–2098. doi:10.4049/jimmunol.180.4.2089

57.

Bao JJ, Fokt I, Szymanski S, Priebe W (2005) Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. Clin Cancer Res 11(24):9026S–9027S

58.

Kupferman ME, Zhou G, Zhao M, Jasser S, Dakak-Yazici Y, Priebe W, Myers JN (2006) A novel inhibitor of STAT3 signaling in head and neck squamous cell carcinoma. In: 97th American Association of Cancer Research Annual Meeting, Washington, DC

59.

Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE Jr, Sampson JH, Priebe W, Heimberger AB (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759–5768PubMedCentralPubMedCrossRef

60.

Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB (2012) The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 131(1):8–17. doi:10.1002/ijc.26307 PubMedCentralPubMedCrossRef

61.

Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26(17):2435–2444. doi:10.1038/sj.onc.1210031

62.

Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB (2010) Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 16(23):5722–5733. doi:10.1158/1078-0432.CCR-10-1693

63.

Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67(20):9630–9636. doi:10.1158/0008-5472.CAN-07-1243

64.

Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB (2010) Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9(1):67–78. doi:10.1158/1535-7163.MCT-09-0734

65.

Sen M, Grandis JR (2012) Nucleic acid-based approaches to STAT inhibition. JAKSTAT 1(4):285–291. doi:10.4161/jkst.22312

66.

Wang X, Crowe PJ, Goldstein D, Yang JL (2012) STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol 41(4):1181–1191. doi:10.3892/ijo.2012.1568 PubMed

67.

Gu J, Li G, Sun T, Su Y, Zhang X, Shen J, Tian Z, Zhang J (2008) Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 89(1):9–17. doi:10.1007/s11060-008-9590-9 PubMedCrossRef

68.

Herrmann A, Priceman SJ, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H (2014) CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest 124(7):2977–2987. doi:10.1172/JCI73174 PubMedCentralPubMedCrossRef

69.

See AP, Han JE, Phallen J, Binder Z, Gallia G, Pan F, Jinasena D, Jackson C, Belcaid Z, Jeong SJ, Gottschalk C, Zeng J, Ruzevick J, Nicholas S, Kim Y, Albesiano E, Pardoll DM, Lim M (2012) The role of STAT3 activation in modulating the immune microenvironment of GBM. J Neurooncol 110(3):359–368. doi:10.1007/s11060-012-0981-6 PubMedCentralPubMedCrossRef

70.

Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB (2013) miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Casncer Res 73(13):3913–3926. doi:10.1158/0008-5472.CAN-12-4318 PubMedCentralPubMedCrossRef

71.

Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, Bhasin D, Regan N, Lin L, Chan C, Caldas H, DeAngelis S, Li C, Li PK, Lin J (2009) LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 100(1):106–112. doi:10.1038/sj.bjc.6604793.6604793 PubMedCentralPubMedCrossRef

72.

Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J (2008) Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol 86(6):506–514. doi:10.1038/icb.2008.27 PubMedCrossRef

73.

Molavi O, Ma Z, Hamdy S, Lavasanifar A, Samuel J (2009) Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124. Immunopharmacol Immunotoxicol 31(2):214–221. doi:10.1080/08923970802380452 PubMedCrossRef

74.

Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB (2010) Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 6(9):2550–2561. doi:10.1158/1078-0432.CCR-10-0279 CrossRef

Title: The role of STAT3 in tumor-mediated immune suppression
Authors: Sherise D. Ferguson
Visish M. Srinivasan
Amy B. Heimberger
Publication date: 01-07-2015
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1731-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of STAT3 in tumor-mediated immune suppression

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Introduction: brain tumor immunotherapy

Cytomegalovirus and glioblastoma; controversies and opportunities

Glioblastoma antigen discovery—foundations for immunotherapy

Concepts of immunotherapy for glioma

The role of IDO in brain tumor immunotherapy

Peptide vaccines for the treatment of glioblastoma